Different metabolic responses to PI3K inhibition in NSCLC cells harboring wild-type and G12C mutant KRAS

KRAS mutations in non-small-cell lung cancer (NSCLC) patients are considered a negative predictive factor and indicate poor response to anticancer treatments. KRAS mutations lead to activation of the PI3K/akt/mTOR pathway, whose inhibition remains a challenging clinical target. Since the PI3K/akt/mT...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Caiola, Elisa, Brunelli, Laura, Marabese, Mirko, Broggini, Massimo, Lupi, Monica, Pastorelli, Roberta
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5239488/
https://ncbi.nlm.nih.gov/pubmed/27283493
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.9849
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky